Skip to main content
Premium Trial:

Request an Annual Quote

Stupid Strong Awards City of Hope $125K for Gastric Cancer Liquid Biopsy Research

NEW YORK – The Stupid Strong Charitable Foundation has awarded Los Angeles-based City of Hope $125,000 to fund a Phase II prospective study to validate micro-RNA biomarkers used to detect early-stage gastric cancer in patients.

The team aims to eventually develop non-invasive, blood-based liquid biopsy assays to diagnose gastric cancer in its early stages.

Ajay Goel, project principal investigator, aims to expand his prior research on the use of circulating biomarkers to develop the assays. He will also leverage the funding to discover and validate biomarkers for peritoneal carcinomas in gastric cancer.

"This pilot funding is seminal in developing proof-of-concept data that could lead to early detection of gastric cancer as well as personalized treatment that could prevent cancer recurrence," Goel said in a statement. "This funding will also help us look for biomarkers that can inform doctors if some patients can be prescribed chemotherapy prior to gastric surgery because their abdominal and pelvic area have peritoneal tumors."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.